Autopsy report · NCT05288543
A Study of Orally Administered IPG7236 in Healthy Adult Participants
Cause of deathFunding or business
“Sponsor decision”
Life of this trial
- Ran for about 3 years 8 months before it stopped.
- 63 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Sponsor type
- Industry
- Conditions
- Atopic Dermatitis
- Interventions
- IPG7236- Single ascending dose; IPG7236- Multiple ascending dose; Placebo (Part A)
- Participants
- 63
- Sites
- 1
- Countries
- Australia
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.